Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9528139 | 0.73 | MGAM (0.30) | — | |
| SCHEMBL10541473 | 0.73 | POLB (0.39) | — | |
| SCHEMBL7629038 | 0.72 | CTSV (0.37) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL10741421 | 0.69 | — | — | |
| SCHEMBL14602377 | 0.67 | CTSV (0.34) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL3337690 | 0.64 | — | — | |
| SCHEMBL3337695 | 0.64 | — | — | |
| SCHEMBL7632547 | 0.62 | CTSV (0.30) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL8168570 | 0.61 | — | — | |
| SCHEMBL10341717 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6451785-B1 | SUBSTITUTED 3-(TRIPHENYLMETHYLAMINO)AZETIDIN-2-ONE; COA-INDEPENDENT TRANSACYLASE (COA-IT) INHIBITOR; COADMINISTERED WITH EDELFOSINE (ET-18-OCH3) OR OTHER ALKYL-LYSOPHOSPHOLIPID ANALOG | SMITHKLINE BEECHAM CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020082250-A1 | BETA LACTAMS AS ANTIPROLIFERATIVE AGENTS | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2002-06-27 | — | — | US | disclosed |
| US-6221860-B1 | Beta-lactam inhibitors of CoA-IT | SMITHKLINE BEECHAM CORPORATION | 2001-04-24 | — | — | US | disclosed |
| EP-1011663-A1 | BETA-LACTAM INHIBITORS OF CoA-IT | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-0982991-A1 | BETA LACTAMS AS ANTIPROLIFERATIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050032-A9 | BETA-LACTAM INHIBITORS OF CoA-IT | SMITHKLINE BEECHAM CORP (US) | 1999-03-25 | — | — | WO | disclosed |
| WO-1998049897-A1 | BETA LACTAMS AS ANTIPROLIFERATIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998050032-A1 | BETA-LACTAM INHIBITORS OF CoA-IT | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082250-A1 | BETA LACTAMS AS ANTIPROLIFERATIVE AGENTS | COASY, LYPLA1, ACAT1 | CTSV 2149/4885CTSL 1095/4885CTSB 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.